Thus, concomitant assessment of both UGT1A1 and DPYD may be particularly valuable in this setting; this is particularly true for CRC patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan—with or without monoclonal antibodies. This evidence concerns the gene DPYD and colorectal carcinoma.